Astrana Health (NASDAQ:ASTH) reports Q3 2026 in line with expectations but quarterly revenue guidance misses expectations
Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B, matching estimates, but missed EPS expectations at $0.71 vs $0.88. Q4 revenue guidance of $989M is below estimates. EBITDA beat slightly at $77.21M. Operating margin improved to 3.9% from 2% YoY.
How this was made

The 30-second read
Why it matters
The earnings miss and weaker guidance are likely to pressure the stock in after‑hours trading, though margin expansion may soften the impact.
Market read
First‑time earnings disclosure with guidance miss; relevant for traders monitoring health‑tech equities.
What to watch
Strong operating margin improvement and stable free cash flow could support a longer‑term upside.
Background
Astrana Health (NASDAQ:ASTH) posted Q3 2026 results with revenue matching estimates, but EPS fell short and guidance for Q4 revenue was below consensus.
Ticker impact
Astrana Health reported Q3 results in line with revenue expectations but missed EPS guidance and issued lower-than-expected Q4 revenue guidance.
likely downside as market prices in weaker guidance
EPS miss and lower revenue outlook suggest weaker near‑term performance, prompting traders to consider short positions or reduce exposure.
Market effects
May weigh on other health‑tech firms with similar business models.
Limited to U.S. biotech/health‑tech segment.
Minimal global impact beyond sector peers.
Counterpoint
If the company can improve margins, the guidance miss may be temporary and present a buying opportunity.
Key entities
- companyAstrana Health
U.S. health‑technology firm reporting Q3 earnings.



